Open an account

Plus Therapeutics

CNSY · NASDAQ

$1.68+$0.03 (+1.82%)TodayMarket closed ·
Prev close $1.65

About CNSY

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 28 full-time employees. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Employees
28
Headquarters
Austin, Texas
Listed
Aug 9, 2000
Sector
Health Care
Industry
Biotechnology
Website
plustherapeutics.com

CNSY key statistics

Market cap
12.75M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
184.21K
Volume
76.93K
Open price
$1.59
High today
$1.77
Low today
$1.58
52 Week high
$18.89
52 Week low
$1.49

Plus Therapeutics (CNSY) at a glance

Plus Therapeutics (CNSY) last traded at $1.68, with a market cap of 12.75M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.58 and $1.77. The current price is 6.7% above the day's low and 5.1% below its high.

Volume so far is 76.93K shares, below the average of 184.21K shares a day.

Over the past year Plus Therapeutics has ranged from $1.49 to $18.89, and now sits 1% of the way up that range.

Plus Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.31 per share against an estimate of -$0.9282.

The average analyst price target is $33.15, 1873.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $33.15
Low
$12.12
Now
$1.68
High
$52.50

CNSY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 53.5% on average.

  1. Q3 FY24: reported -$9.25 per share against an estimate of -$14.34
  2. Q4 FY24: reported -$12.25 per share against an estimate of -$12.67
  3. Q1 FY25: reported -$29.75 per share against an estimate of -$3.74
  4. Q2 FY25: reported $0.50 per share against an estimate of -$2.30
  5. Q3 FY25: reported -$1.00 per share against an estimate of -$0.51
  6. Q4 FY25: reported -$1.04 per share against an estimate of -$0.8288
  7. Q1 FY26: reported -$1.05 per share against an estimate of -$0.8976
  8. Q2 FY26: reported -$1.31 per share against an estimate of -$0.9282

CNSY news

  • 12 Health Care Stocks Moving In Friday's After-Market Session

Similar companies

Companies in the same industry as Plus Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.